Pacific Edge (PEB.NZ) Stock Price

Pacific Edge Price

NZX·CLOSED
0.26NZD+0.00 (+0.00 %)
Market closed

Revenue has compounded at 19.7% per year over the past 19 years to 21.85 M NZD. Pacific Edge's net margin stands at -137.0%, up from -184.7% several years earlier. Analysts set a median price target of 0.13 NZD, implying 51.9% below the current price. Of 8 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 160% above its 52-week low.

Pacific Edge stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Pacific Edge over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Pacific Edge stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Pacific Edge's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Pacific Edge Stock Price History
DatePacific Edge Price
8/10/20260.26 NZD
8/7/20260.26 NZD
8/6/20260.27 NZD
8/5/20260.27 NZD
8/4/20260.27 NZD
8/3/20260.26 NZD
7/31/20260.28 NZD
7/30/20260.27 NZD
7/29/20260.26 NZD
7/28/20260.25 NZD
7/27/20260.26 NZD
7/24/20260.26 NZD
7/23/20260.26 NZD
7/22/20260.27 NZD
7/21/20260.25 NZD
7/20/20260.26 NZD
7/17/20260.27 NZD
7/16/20260.28 NZD
7/15/20260.28 NZD
7/14/20260.28 NZD
7/13/20260.28 NZD
7/9/20260.28 NZD
7/8/20260.29 NZD
7/7/20260.28 NZD
7/6/20260.29 NZD
7/3/20260.29 NZD
7/2/20260.30 NZD
7/1/20260.30 NZD
6/30/20260.30 NZD
6/29/20260.31 NZD
6/26/20260.30 NZD
6/25/20260.31 NZD
6/24/20260.30 NZD
6/23/20260.30 NZD
6/22/20260.31 NZD
6/19/20260.31 NZD
6/18/20260.31 NZD
6/17/20260.31 NZD
6/16/20260.31 NZD
6/15/20260.30 NZD
6/12/20260.30 NZD
6/11/20260.31 NZD
6/10/20260.31 NZD
6/9/20260.31 NZD
6/8/20260.30 NZD
6/5/20260.30 NZD
6/4/20260.28 NZD
6/3/20260.28 NZD
6/2/20260.28 NZD
5/29/20260.28 NZD
5/28/20260.26 NZD
5/27/20260.27 NZD
5/26/20260.27 NZD
5/25/20260.28 NZD
5/22/20260.27 NZD
5/21/20260.28 NZD
5/20/20260.28 NZD
5/19/20260.30 NZD
5/18/20260.28 NZD
5/15/20260.27 NZD
5/14/20260.17 NZD
5/13/20260.17 NZD
5/12/20260.17 NZD
5/11/20260.17 NZD
5/8/20260.17 NZD
5/7/20260.18 NZD
5/6/20260.17 NZD
5/5/20260.17 NZD
5/4/20260.17 NZD
5/1/20260.17 NZD
4/30/20260.17 NZD
4/29/20260.17 NZD
4/28/20260.17 NZD
4/24/20260.17 NZD
4/23/20260.17 NZD
4/22/20260.17 NZD
4/21/20260.17 NZD
4/20/20260.18 NZD
4/17/20260.18 NZD
4/16/20260.18 NZD
4/15/20260.19 NZD
4/14/20260.19 NZD
4/13/20260.19 NZD
4/10/20260.19 NZD
4/9/20260.19 NZD
4/8/20260.19 NZD
4/7/20260.18 NZD
4/2/20260.17 NZD
4/1/20260.17 NZD
3/31/20260.17 NZD
3/30/20260.17 NZD
3/27/20260.18 NZD
3/26/20260.18 NZD
3/25/20260.18 NZD
3/24/20260.18 NZD
3/23/20260.18 NZD
3/20/20260.18 NZD
3/19/20260.18 NZD
3/18/20260.18 NZD
3/17/20260.19 NZD
3/16/20260.20 NZD
3/13/20260.20 NZD
3/12/20260.20 NZD
3/11/20260.20 NZD
3/10/20260.19 NZD
3/9/20260.20 NZD
3/6/20260.20 NZD
3/5/20260.20 NZD
3/4/20260.20 NZD
3/3/20260.20 NZD
3/2/20260.20 NZD
2/27/20260.20 NZD
2/26/20260.20 NZD
2/25/20260.22 NZD
2/24/20260.23 NZD
2/23/20260.24 NZD
2/20/20260.22 NZD
2/19/20260.22 NZD
2/18/20260.22 NZD
2/17/20260.21 NZD
2/16/20260.22 NZD
2/13/20260.22 NZD
2/12/20260.22 NZD
2/11/20260.23 NZD
2/10/20260.22 NZD
2/9/20260.20 NZD
2/5/20260.19 NZD
2/4/20260.18 NZD
2/3/20260.18 NZD
2/2/20260.19 NZD
1/30/20260.19 NZD
1/29/20260.20 NZD
1/28/20260.20 NZD
1/27/20260.20 NZD
1/26/20260.19 NZD
1/23/20260.18 NZD
1/22/20260.19 NZD
1/21/20260.18 NZD
1/20/20260.18 NZD
1/19/20260.19 NZD
1/16/20260.19 NZD
1/15/20260.19 NZD
1/14/20260.19 NZD
1/13/20260.19 NZD
1/12/20260.19 NZD
1/9/20260.18 NZD
1/8/20260.18 NZD
1/7/20260.17 NZD
1/6/20260.17 NZD
1/5/20260.18 NZD
12/31/20250.19 NZD
12/30/20250.19 NZD
12/29/20250.18 NZD
12/24/20250.17 NZD
12/23/20250.17 NZD
12/22/20250.17 NZD
12/19/20250.17 NZD
12/18/20250.16 NZD
12/17/20250.16 NZD
12/16/20250.15 NZD
12/15/20250.16 NZD
12/12/20250.16 NZD
12/11/20250.16 NZD
12/10/20250.16 NZD
12/9/20250.16 NZD
12/8/20250.16 NZD
12/5/20250.16 NZD
12/4/20250.16 NZD
12/3/20250.16 NZD
12/2/20250.16 NZD
12/1/20250.15 NZD
11/28/20250.15 NZD
11/27/20250.14 NZD
11/26/20250.15 NZD
11/25/20250.17 NZD
11/24/20250.18 NZD
11/21/20250.17 NZD
11/20/20250.18 NZD
11/19/20250.17 NZD
11/18/20250.17 NZD
11/17/20250.17 NZD
11/14/20250.17 NZD
11/13/20250.17 NZD
11/12/20250.17 NZD
11/11/20250.17 NZD
11/10/20250.17 NZD
11/7/20250.18 NZD
11/6/20250.18 NZD
11/5/20250.19 NZD
11/4/20250.19 NZD
11/3/20250.19 NZD
10/31/20250.19 NZD
10/30/20250.19 NZD
10/29/20250.19 NZD
10/28/20250.19 NZD
10/24/20250.19 NZD
10/23/20250.19 NZD
10/22/20250.19 NZD
10/21/20250.19 NZD
10/20/20250.19 NZD
10/17/20250.19 NZD
10/16/20250.19 NZD
10/15/20250.19 NZD
10/14/20250.19 NZD
10/13/20250.19 NZD
10/10/20250.19 NZD
10/9/20250.20 NZD
10/8/20250.20 NZD
10/7/20250.20 NZD
10/6/20250.19 NZD
10/3/20250.20 NZD
10/2/20250.20 NZD
10/1/20250.20 NZD
9/30/20250.19 NZD
9/29/20250.19 NZD
9/26/20250.19 NZD
9/25/20250.18 NZD
9/24/20250.17 NZD
9/23/20250.17 NZD
9/22/20250.17 NZD
9/19/20250.18 NZD
9/18/20250.18 NZD
9/17/20250.19 NZD
9/16/20250.19 NZD
9/15/20250.20 NZD
9/12/20250.16 NZD
9/11/20250.16 NZD
9/10/20250.16 NZD
9/9/20250.14 NZD
9/8/20250.14 NZD
9/5/20250.14 NZD
9/4/20250.14 NZD
9/3/20250.14 NZD
9/2/20250.14 NZD
9/1/20250.14 NZD
8/29/20250.14 NZD
8/28/20250.14 NZD
8/27/20250.14 NZD
8/26/20250.14 NZD
8/25/20250.14 NZD
8/22/20250.13 NZD
8/21/20250.12 NZD
8/20/20250.13 NZD
8/19/20250.13 NZD
8/18/20250.12 NZD
8/15/20250.11 NZD
8/14/20250.11 NZD
8/13/20250.10 NZD
Access this data via the Eulerpool API
Get Free API Key

Pacific Edge Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
11.45 M NZD
-20.51 M NZD
-19.79 M NZD
Jan 1, 2023
19.62 M NZD
-32.04 M NZD
-26.97 M NZD
Jan 1, 2024
23.91 M NZD
-33.58 M NZD
-29.54 M NZD
Jan 1, 2025
21.85 M NZD
-31.77 M NZD
-29.94 M NZD
Jan 1, 2026 (e)
12.45 M NZD
-12.45 M NZD
-38.15 M NZD
Jan 1, 2027 (e)
18.67 M NZD
-18.67 M NZD
-27.06 M NZD
Jan 1, 2028 (e)
36.67 M NZD
-36.67 M NZD
-17.59 M NZD
Jan 1, 2029 (e)
59.65 M NZD
-59.65 M NZD
-2.44 M NZD

Pacific Edge Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 12, 2026, 2:50 AM
 
REVENUEM NZD
REVENUE GROWTH%
EBITM NZD
EBIT MARGIN%
NET INCOMEM NZD
NET INCOME GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
–1.004.003.003.003.004.007.0011.0019.0023.0021.0012.0018.0036.0059.00
––300.00-25.00––33.3375.0057.1472.7321.05-8.70-42.8650.00100.0063.89
-9.00-13.00-16.00-22.00-20.00-18.00-19.00-15.00-20.00-32.00-33.00-31.00-12.00-18.00-36.00-59.00
–-1,300.00-400.00-733.33-666.67-600.00-475.00-214.29-181.82-168.42-143.48-147.62-100.00-100.00-100.00-100.00
-9.00-12.00-15.00-22.00-19.00-17.00-18.00-14.00-19.00-26.00-29.00-29.00-38.00-27.00-17.00-2.00
50.0033.3325.0046.67-13.64-10.535.88-22.2235.7136.8411.54–31.03-28.95-37.04-88.24
314.64341.69387.48425.02463.70513.78581.34714.03767.92810.23810.73811.74811.74811.74811.74811.74
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Pacific Edge generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Pacific Edge retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Pacific Edge's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Pacific Edge has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Pacific Edge's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Pacific Edge stock margins

The Pacific Edge margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pacific Edge. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pacific Edge.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
100.00 %
-203.19 %
-184.69 %
Jan 1, 2022
100.00 %
-179.18 %
-172.90 %
Jan 1, 2023
100.00 %
-163.35 %
-137.46 %
Jan 1, 2024
100.00 %
-140.45 %
-123.54 %
Jan 1, 2025
100.00 %
-145.42 %
-137.03 %
Jan 1, 2026 (e)
100.00 %
-100.00 %
-306.44 %
Jan 1, 2027 (e)
100.00 %
-100.00 %
-144.95 %
Jan 1, 2028 (e)
100.00 %
-100.00 %
-47.97 %

Pacific Edge Stock Revenue, EBIT, Earnings per Share

The Pacific Edge earnings per share therefore indicates how much revenue Pacific Edge has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.01 NZD
-0.02 NZD
-0.02 NZD
Jan 1, 2022
0.01 NZD
-0.03 NZD
-0.03 NZD
Jan 1, 2023
0.02 NZD
-0.04 NZD
-0.03 NZD
Jan 1, 2024
0.03 NZD
-0.04 NZD
-0.04 NZD
Jan 1, 2025
0.03 NZD
-0.04 NZD
-0.04 NZD
Jan 1, 2026 (e)
0.02 NZD
-0.02 NZD
-0.05 NZD
Jan 1, 2027 (e)
0.02 NZD
-0.02 NZD
-0.03 NZD
Jan 1, 2028 (e)
0.05 NZD
-0.05 NZD
-0.02 NZD

Pacific Edge business model & stock analysis

Pacific Edge Ltd is a company based in New Zealand specializing in the development and marketing of cancer diagnostic test systems. The company was founded in 2001 and has since become a leading provider of cancer detection systems in New Zealand and other countries. Pacific Edge's business model is based on the development and marketing of non-invasive diagnostic methods for early cancer detection. The tests offered are based on the analysis of urine samples, which are analyzed using state-of-the-art technologies to detect specific proteins in the urine that are typically associated with cancer. These tests enable doctors and patients to detect cancer at an early stage, increasing treatment and cure rates. Pacific Edge specializes in three main areas: urology, gynecology, and bladder cancer. The urology division focuses on the development of diagnostic tests for prostate cancer. It is one of the most common types of cancer in men, and early detection is known to increase the chance of a complete cure. Tests such as Cxbladder enable doctors to detect prostate cancer at an early stage. Pacific Edge's gynecology division focuses on the development of diagnostic tests for the early detection of cervical cancer. Currently, the Pap test is used in many countries to detect the presence of cancer cells in the cervix. However, the Cxbladder diagnostic test can detect the presence of certain proteins in the urine that indicate a cancerous condition, without the need for invasive procedures. The third pillar of Pacific Edge is the bladder cancer division. The Cxbladder test enables doctors to detect bladder cancer at an early stage. Currently, there are few effective screening methods for bladder cancer. However, the Cxbladder test can help detect bladder cancer at an early stage, improving treatment and cure rates. In addition to the three main areas, Pacific Edge also develops new diagnostic products for other types of cancer. These include cancers such as colon cancer, lung cancer, and kidney cancer, as well as rare cancers such as pancreatic cancer and esophageal cancer. Pacific Edge's products have already proven themselves in the medical community. They provide doctors and patients with an effective and cost-efficient way to detect cancer early. The company also conducts research and development to improve the accuracy and effectiveness of the tests offered. Pacific Edge is committed to expanding its business globally. It has already formed partnerships with some leading pharmaceutical and biotech companies to distribute its products on a global scale. The company has also established offices in Australia, the United States, and Singapore. In summary, Pacific Edge Ltd is a company specializing in the development and marketing of diagnostic tests for cancer. It focuses on the early detection of cancers such as prostate cancer, cervical cancer, and bladder cancer through the analysis of urine samples using state-of-the-art technologies. The company has established itself as a leading provider of cancer detection systems and conducts research and development to improve the accuracy and effectiveness of its products. Pacific Edge is committed to expanding its business globally and has already formed partnerships with leading companies in the pharmaceutical and biotech industry.

Pacific Edge SWOT Analysis

Strengths

Pacific Edge Ltd has several strengths that contribute to its success in the market. The company has a strong focus on innovation and research, allowing it to develop cutting-edge diagnostic tests with high accuracy rates. Its advanced technology and expertise in molecular diagnostics give it a competitive advantage in the healthcare industry.

Additionally, Pacific Edge Ltd has built strategic partnerships with leading healthcare providers and institutions, enabling it to expand its market reach and increase the adoption of its diagnostic tests. These partnerships also provide access to valuable data and patient samples for research and development purposes.

Pacific Edge Ltd also faces certain weaknesses that could hinder its growth and competitiveness. One of the main weaknesses is the company's limited geographical presence. Although it has a strong presence in New Zealand, its market penetration in other regions, such as the United States, is less significant. This limits its potential customer base and revenue opportunities.

Another weakness is the dependency on key partnerships and collaborations for data and sample acquisition. Any disruptions or termination of these partnerships could affect the company's ability to conduct research and develop new diagnostic tests.

Pacific Edge Ltd has several opportunities for growth and expansion. The increasing demand for personalized medicine and targeted cancer treatments provides a favorable market environment for the company's molecular diagnostics tests. By leveraging its advanced technology and expertise, the company can further develop its product portfolio to cater to this growing demand.

Furthermore, expanding its geographical presence, especially in large markets like the United States, can significantly increase Pacific Edge Ltd's customer base and revenue potential. This can be achieved through strategic partnerships, acquisitions, or establishing direct sales and distribution channels.

Pacific Edge Ltd faces certain threats in the competitive healthcare industry. One of the main threats is the presence of well-established competitors with similar diagnostic products and technologies. These competitors may have larger market shares, stronger brand recognition, and more extensive distribution networks, making it challenging for Pacific Edge Ltd to gain market share.

Additionally, regulatory and reimbursement challenges can impact the adoption and utilization of the company's diagnostic tests. Changes in healthcare policies and reimbursement rates can create uncertainties and restrict access to certain markets or patient populations.

Weaknesses

Pacific Edge Ltd also faces certain weaknesses that could hinder its growth and competitiveness. One of the main weaknesses is the company's limited geographical presence. Although it has a strong presence in New Zealand, its market penetration in other regions, such as the United States, is less significant. This limits its potential customer base and revenue opportunities.

Another weakness is the dependency on key partnerships and collaborations for data and sample acquisition. Any disruptions or termination of these partnerships could affect the company's ability to conduct research and develop new diagnostic tests.

Pacific Edge Ltd has several opportunities for growth and expansion. The increasing demand for personalized medicine and targeted cancer treatments provides a favorable market environment for the company's molecular diagnostics tests. By leveraging its advanced technology and expertise, the company can further develop its product portfolio to cater to this growing demand.

Furthermore, expanding its geographical presence, especially in large markets like the United States, can significantly increase Pacific Edge Ltd's customer base and revenue potential. This can be achieved through strategic partnerships, acquisitions, or establishing direct sales and distribution channels.

Pacific Edge Ltd faces certain threats in the competitive healthcare industry. One of the main threats is the presence of well-established competitors with similar diagnostic products and technologies. These competitors may have larger market shares, stronger brand recognition, and more extensive distribution networks, making it challenging for Pacific Edge Ltd to gain market share.

Additionally, regulatory and reimbursement challenges can impact the adoption and utilization of the company's diagnostic tests. Changes in healthcare policies and reimbursement rates can create uncertainties and restrict access to certain markets or patient populations.

Opportunities

Pacific Edge Ltd has several opportunities for growth and expansion. The increasing demand for personalized medicine and targeted cancer treatments provides a favorable market environment for the company's molecular diagnostics tests. By leveraging its advanced technology and expertise, the company can further develop its product portfolio to cater to this growing demand.

Furthermore, expanding its geographical presence, especially in large markets like the United States, can significantly increase Pacific Edge Ltd's customer base and revenue potential. This can be achieved through strategic partnerships, acquisitions, or establishing direct sales and distribution channels.

Pacific Edge Ltd faces certain threats in the competitive healthcare industry. One of the main threats is the presence of well-established competitors with similar diagnostic products and technologies. These competitors may have larger market shares, stronger brand recognition, and more extensive distribution networks, making it challenging for Pacific Edge Ltd to gain market share.

Additionally, regulatory and reimbursement challenges can impact the adoption and utilization of the company's diagnostic tests. Changes in healthcare policies and reimbursement rates can create uncertainties and restrict access to certain markets or patient populations.

Threats

Pacific Edge Ltd faces certain threats in the competitive healthcare industry. One of the main threats is the presence of well-established competitors with similar diagnostic products and technologies. These competitors may have larger market shares, stronger brand recognition, and more extensive distribution networks, making it challenging for Pacific Edge Ltd to gain market share.

Additionally, regulatory and reimbursement challenges can impact the adoption and utilization of the company's diagnostic tests. Changes in healthcare policies and reimbursement rates can create uncertainties and restrict access to certain markets or patient populations.

Pacific Edge Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Pacific Edge historical P/E ratio, EBIT multiple, and P/S ratio

Pacific Edge annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Pacific Edge shares outstanding

The number of shares of Pacific Edge was 811.74 M in 2025. This indicates how many shares Pacific Edge is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
714.03 M Stocks
Jan 1, 2022
767.92 M Stocks
Jan 1, 2023
810.23 M Stocks
Jan 1, 2024
810.73 M Stocks
Jan 1, 2025
811.74 M Stocks
Jan 1, 2026 (e)
811.74 M Stocks
Jan 1, 2027 (e)
811.74 M Stocks
Jan 1, 2028 (e)
811.74 M Stocks

Current Pacific Edge forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
0.00 % (0)
Hold
37.50 % (3)
Sell
62.50 % (5)
12M Price Target
0.13
Last Price
0.26
Currency
NZD
12M Return Potential
-51.89 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the Pacific Edge stock

47/100
49
Environment
63
Social
30
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Pacific Edge shareholder structure

% Name
13.15261%
Harbour Asset Management Limited
Harbour Asset Management Limited
6.23772%
BT Funds Management (New Zealand) Ltd.
BT Funds Management (New Zealand) Ltd.
2.37951%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
0.09855%
FCA Corp.
FCA Corp.
0.06589%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
0.02412%
Dimensional Fund Advisors, Ltd.
Dimensional Fund Advisors, Ltd.

Pacific Edge Beneficial Ownership Filings (SEC 13D/G)

Free Float
92.3%
Float Shares
-
Shares Outstanding
-

Pacific Edge Executives and Management Board

15 members · avg. age 58 · 13 % women

PM

Dr. Peter Meintjes

Chief Executive Officer

889,000.00 NZD

Management

DL

Mr. David Levison (58)

President of Pacific Edge Diagnostics USA · since 2016

53,000.00 NZD
GG

Mr. Grant Edward Gibson

Chief Financial Officer

–
GC

Mr. Glen Costin

President, Asia Pacific

–
DM

Mr. Darrell Morgan

Chief Operating Officer

–
JH

Dr. Justin Harvey

Chief Technology Officer

–
PG

Prof. Parry Guilford

Chief Scientific Officer

–

Board of Directors

CG

Mr. Chris Gallaher

Non-Executive Independent Chairman of the Board

115,000.00 NZD
SP

Ms. Sarah Natalie Park

Non-Executive Independent Director

70,000.00 NZD
BW

Dr. Bryan Williams

Non-Executive Independent Director

70,000.00 NZD
AS

Ms. Anna Stove

Non-Executive Independent Director

65,000.00 NZD
TB

Mr. Tony Barclay

Non-Executive Independent Director

60,000.00 NZD
AM

Mr. Anatole Masfen

Non-Executive Independent Director

60,000.00 NZD

Frequently asked questions about Pacific Edge

The business model of Pacific Edge Ltd is centered around personalized medicine and diagnostic tests. The company specializes in developing and commercializing innovative molecular diagnostic tests that help in the detection and management of cancer. By leveraging advanced technologies, Pacific Edge aims to provide accurate, non-invasive, and cost-effective solutions for early detection and monitoring of various types of cancer. The company's focus on precision medicine enables healthcare professionals to make informed decisions regarding patient treatment, ultimately improving outcomes and reducing healthcare costs. Pacific Edge Ltd is committed to ongoing research and development to expand their portfolio of diagnostic tests and make a positive impact on global cancer care.

Pacific Edge Ltd is primarily active in the healthcare industry.

Some of the main competitors of Pacific Edge Ltd in the market include companies such as Exact Sciences Corp, Genomic Health Inc, and Myriad Genetics Inc.

Pacific Edge Ltd is a New Zealand-based biotechnology company. Established in 2001, Pacific Edge specializes in the discovery and development of diagnostic and prognostic tools for the early detection and monitoring of various cancers. With a focus on urology and the detection of bladder cancer, Pacific Edge has developed a range of proprietary diagnostic tests, including Cxbladder, which has gained recognition worldwide. The company has garnered partnerships and collaborations with various healthcare organizations and research institutes, enabling them to expand their portfolio and global presence. Pacific Edge Ltd continues to innovate and provide cutting-edge solutions in the field of cancer diagnostics.

Pacific Edge Ltd has achieved several significant milestones in its journey. The company successfully developed and commercialized its Cxbladder range of non-invasive, accurate bladder cancer diagnostics. It has established partnerships and distribution agreements with reputed healthcare organizations worldwide, expanding its market reach. Pacific Edge Ltd has also made advancements in its product portfolio, introducing innovative features and improvements to enhance diagnostic accuracy and patient outcomes. Additionally, the company has gained recognition from the medical community, receiving numerous awards and accolades for its groundbreaking diagnostic solutions. Overall, Pacific Edge Ltd has demonstrated relentless commitment to pioneering advancements in bladder cancer diagnostics, solidifying its position as a leader in the field.

Pacific Edge Ltd is primarily present in New Zealand, the United States, Australia, and Canada.

Pacific Edge Ltd represents a commitment to excellence, innovation, and cutting-edge technology within the healthcare industry. With a focus on precision medicine, the company strives to provide accurate and reliable diagnostic solutions for the early detection and monitoring of various cancers. Pacific Edge firmly believes in patient-centric care, ensuring that individuals receive timely and personalized treatment options. The company's corporate philosophy revolves around improving patient outcomes, enhancing healthcare practices, and driving sustainable growth through ongoing research and development. With Pacific Edge Ltd, investors can have confidence in a company that is dedicated to making a positive impact on cancer management worldwide.

Analysts currently set an average price target of 0.13 NZD for the Pacific Edge stock (median: 0.13 NZD), implying -51.9 % versus the latest price. The consensus is based on 8 analyst ratings.

Pacific Edge Analyst Price Targets 2026

8 analysts currently rate the Pacific Edge stock: 0 recommend buying, 3 holding and 5 selling. For 2026, analysts expect Pacific Edge to generate revenue of 12.45 M NZD and earnings per share of -0.05 NZD.

Pacific Edge Analyst Price Targets 2026

Converted at the current exchange rate, the Pacific Edge share trades at 0.14 EUR (0.26 NZD).

The Pacific Edge share (PEB.NZ) is listed on 4 stock exchanges, including: ASX (PEB.AX).

Pacific Edge Limited is a New Zealand company specializing in the development and marketing of cancer diagnostics and therapy products. The company operates in three business areas: urology, gynecology, and gastroenterology. In urology, they offer Cxbladder, a non-invasive urine test for diagnosing bladder cancer. In gynecology, they have developed the EndometrialScratch test for early detection of endometrial cancer. And in gastroenterology, they provide the ColonoGuard test, a non-invasive blood-based test for diagnosing colon cancer. Their business model involves international marketing of their products and services, partnering with diagnostic and healthcare companies, and establishing a strong presence in the US market. Their competitive advantages are their unique and effective diagnostic technology and their global market presence. Overall, Pacific Edge aims to improve cancer diagnosis and treatment worldwide.

The expected revenue of Pacific Edge is 12.45 M NZD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Pacific Edge is -38.15 M NZD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Pacific Edge is currently -5.64. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pacific Edge stock.

The price-to-sales ratio (P/S) of Pacific Edge is currently 17.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pacific Edge stock.

The Eulerpool Quality Score for Pacific Edge is 4/10.

The ISIN of Pacific Edge is NZPEBE0002S1. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Pacific Edge is A1JQAD. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Pacific Edge is PEB.NZ. The ticker symbol is used to trade Pacific Edge shares on the stock exchange.

Pacific Edge paid dividends every year for the past 0 years.

Pacific Edge is assigned to the 'Health' sector.

The dividends of Pacific Edge are distributed in NZD.

All fundamentals and in-depth analysis of Pacific Edge

Our stock analysis for Pacific Edge stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pacific Edge. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Pacific Edge Stock
Pacific Edge Revenue→
Pacific Edge Stock
Pacific Edge Net Income→
Pacific Edge Stock
Pacific Edge P/E→
Pacific Edge Stock
Pacific Edge P/S→
Pacific Edge Stock
Pacific Edge EBIT→
Pacific Edge Stock
Pacific Edge Dividend→
Pacific Edge Stock
Pacific Edge Directors Dealings→
Pacific Edge Stock
Pacific Edge Stocks→
Pacific Edge Stock
Pacific Edge Market capitalization→
Pacific Edge Stock
Pacific Edge Debt→
Pacific Edge Stock
Pacific Edge Liabilities→
Pacific Edge Stock
Pacific Edge Equity→
Pacific Edge Stock
Pacific Edge AAQS→
Pacific Edge Stock
Pacific Edge Employees→
Pacific Edge Stock
Pacific Edge ROE→
Pacific Edge Stock
Pacific Edge ROA→
Pacific Edge Stock
Pacific Edge ROCE→
Pacific Edge Stock
Pacific Edge News→
Pacific Edge Stock
Pacific Edge Analyst Price Targets→

Health Stocks

Pacific Health Care OrganizationPacific Biosciences of CaliforniaPacific Hospital Supply CoP3 Health PartnersPacific Shuanglin Bio-pharmacy CoP&S Robotics CoPacira BiosciencesP&K Skin Research Center CoPainChekOxurionPaionOxford Nanopore TechnologiesAll Stocks A–Z →